Healthcare provider profile · identity verified

Bryson Kemler

Allopathic & Osteopathic Physicians|Orthopaedic Surgery · CHESAPEAKE, VA · NPI 1417510678

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Bryson Kemler received $9,992.39 in general payments during 2025 across 87 reported records.

Smith+Nephew, Inc. accounted for 46.4% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 24 associated products.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$9,992.39

87 reported records · 8 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported companyCanonical companyAmountShareRecordsYear
Smith+Nephew, Inc. Unresolved — no canonical attribution shown $4,632.6346.4%322025
Stryker Corporation Unresolved — no canonical attribution shown $2,821.8228.2%302025
Arthrex, Inc. Unresolved — no canonical attribution shown $1,407.9914.1%122025
Shoulder Innovations, Inc. Unresolved — no canonical attribution shown $724.517.2%52025
Fortis Surgical, LLC Unresolved — no canonical attribution shown $289.102.9%42025
Vericel Corporation Unresolved — no canonical attribution shown $50.000.5%12025
Bioventus LLC Unresolved — no canonical attribution shown $37.470.4%22025
Linvatec Corporation Unresolved — no canonical attribution shown $28.870.3%12025

What were the payments for?

Payment categories

CategoryAmountRecords
Food and Beverage$3,885.7372
Grant$2,916.671
Travel and Lodging$2,849.7011
Education$316.442
Gift$23.851

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported productTypeReported companyRelated amount*RecordsYear
MAKO
Normalized: mako
Device Stryker Corporation $1,803.22 19 2025
Source payment records
InSet System
Normalized: inset system
Device Shoulder Innovations, Inc. $724.51 5 2025
Source payment records
N/A
Normalized: n a
Device Smith+Nephew, Inc. $581.33 9 2025
Source payment records
AEQUALIS PERFORM
Normalized: aequalis perform
Device Stryker Corporation $483.43 3 2025
Source payment records
Bioinductive Implant with Arthroscopic Delivery System - Medium
Normalized: bioinductive implant with arthroscopic delivery system medium
Device Smith+Nephew, Inc. $461.94 7 2025
Source payment records
BLUEPRINT PATIENT SPECIFIC INSTRUMENTATION
Normalized: blueprint patient specific instrumentation
Device Stryker Corporation $317.25 4 2025
Source payment records
Q-FIX
Normalized: q fix
Device Smith+Nephew, Inc. $313.03 5 2025
Source payment records
Bone Anchors with Arthroscopic Delivery System
Normalized: bone anchors with arthroscopic delivery system
Device Smith+Nephew, Inc. $284.03 3 2025
Source payment records
ALPHAVENT
Normalized: alphavent
Device Stryker Corporation $249.72 3 2025
Source payment records
AEQUALIS ASCEND FLEX
Normalized: aequalis ascend flex
Device Stryker Corporation $166.99 1 2025
Source payment records
INSIGNIA
Normalized: insignia
Device Stryker Corporation $112.97 1 2025
Source payment records
ACUFEX
Normalized: acufex
Device Smith+Nephew, Inc. $51.67 2 2025
Source payment records
MACI
Normalized: maci
Biological Vericel Corporation $50.00 1 2025
Source payment records
INSPACE
Normalized: inspace
Device Stryker Corporation $44.08 1 2025
Source payment records
KNOTILUS ANCHOR, 3.5MM
Normalized: knotilus anchor 3 5mm
Device Stryker Corporation $44.08 1 2025
Source payment records
XBRAID
Normalized: xbraid
Device Stryker Corporation $44.08 1 2025
Source payment records
RF20000
Normalized: rf20000
Device Smith+Nephew, Inc. $32.56 1 2025
Source payment records
BIOBRACE 23MM
Normalized: biobrace 23mm
Device Linvatec Corporation $28.87 1 2025
Source payment records
AMBIENT
Normalized: ambient
Device Smith+Nephew, Inc. $22.33 2 2025
Source payment records
AEQUALIS PERFORM REVERSED
Normalized: aequalis perform reversed
Device Stryker Corporation $22.22 1 2025
Source payment records
EXOGEN ULTRASOUND BONE HEALING SYSTEM
Normalized: exogen ultrasound bone healing system
Device Bioventus LLC $20.61 1 2025
Source payment records
XCELL
Normalized: xcell
Device Bioventus LLC $16.86 1 2025
Source payment records
ACUFEX DIRECTOR
Normalized: acufex director
Device Smith+Nephew, Inc. $6.15 1 2025
Source payment records
CAP-FIX
Normalized: cap fix
Device Smith+Nephew, Inc. $3.30 1 2025
Source payment records

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

BrandGenericClaimsBeneficiaries
Doxycycline MonohydrateDoxycycline Monohydrate1514
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen1312

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

YearGeneral PaymentsMain payerExplicit productsCompany overlapsPart D coverage
2025 $9,992.39 · 87 records Smith+Nephew, Inc. ACUFEX, ACUFEX DIRECTOR, AEQUALIS ASCEND FLEX, AEQUALIS PERFORM, AEQUALIS PERFORM REVERSED, ALPHAVENT, AMBIENT, BIOBRACE 23MM, BLUEPRINT PATIENT SPECIFIC INSTRUMENTATION, Bioinductive Implant with Arthroscopic Delivery System - Medium, Bone Anchors with Arthroscopic Delivery System, CAP-FIX, EXOGEN ULTRASOUND BONE HEALING SYSTEM, INSIGNIA, INSPACE, InSet System, KNOTILUS ANCHOR, 3.5MM, MACI, MAKO, N/A, Q-FIX, RF20000, XBRAID, XCELL
2024 Complete

Questions to ask

Questions you could discuss with your doctor

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Loaded source releases

DatasetYearPublicationSource
CMS Open Payments — General Payments 2025 2026-06-30 Original source
Medicare Part D Prescribers by Provider and Drug 2024 2026-05-06 Original source
NPPES Data Dissemination V2 current / reference data 2026-08-10 Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error